59 articles in this topic
The CLEAR Harmony trial tested bempedoic acid's safety in statin-intolerant patients with uncontrolled LDL and high cardiovascular risk.
A completed Montreal trial tested remote physical and cognitive training in 122 older adults with cardiovascular disease.
A completed University of Florida trial probes why aerobic exercise improves artery function in older men but yields inconsistent results in postmenopausal women.
A Phase 2 trial tests whether selatogrel, a subcutaneous P2Y12 inhibitor, can rapidly block platelet aggregation in stable coronary artery disease patients.
Mayo Clinic tests whether 6 months of the SGLT2 inhibitor dapagliflozin can reduce exercise-induced cardiac pressure in preserved-ejection-fraction heart failure.
A pilot RCT tests whether a values-based psychological intervention can improve medication adherence in heart failure patients undergoing cardiac rehab.
An 80-week Amgen-sponsored Phase 3 trial evaluated evolocumab's safety and efficacy in pediatric patients aged 10–17 with inherited high LDL cholesterol.
A Phase 2 trial tests whether a fixed-dose combination pill can safely lower LDL cholesterol in people with type 2 diabetes.
A Phase 3 trial pits monthly lerodalcibep against evolocumab in homozygous familial hypercholesterolemia patients over 24 weeks.
Merck's CETP inhibitor anacetrapib was evaluated alongside statin therapy to assess LDL-C lowering and HDL-C raising in hypercholesterolemia patients.
A Phase 2 trial pits NNC0385-0434 tablets against evolocumab injections in high-risk cardiovascular patients — could a daily pill replace the shot?
Amgen's siRNA therapy olpasiran targets lipoprotein(a), a stubborn cardiovascular risk factor with no approved treatments.
